Other

Gilead in $21 bn deal for Immunomedics

US pharmaceutical giant Gilead Sciences confirmed Sunday that it is buying American biotech firm Immunomedics, which makes a breast cancer drug, for $21 billion.

Obstetrics & gynaecology

Women's wellness: Cervical cancer screening guidelines updated

Cervical cancer used to be one of the top causes of cancer for women in the U.S. But over the past decade, rates have been declining. As a result, the American Cancer Society recently updated its guidelines about when women ...

page 2 from 12